Find information on thousands of medical conditions and prescription drugs.

Faslodex

Fulvestrant is a drug treatment of hormone receptor positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects and down-regulates the estrogen receptor. It is administered as a once-monthly injection.

Fulvestrant is marketed by AstraZeneca with the brand name Faslodex.

A

B

C

D

E

F

Fludrocortisone

Fluorometholone

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Read more at Wikipedia.org

• [List your site here Free!]



	AstraZeneca received FDA approval for Faslodex - Branded News - Brief Article - Product Announcement AstraZeneca received FDA approval for Faslodex (fulvestrant), a treatment for hormone receptor positive metastatic breast cancer in postmenopausal women ... From Drug Store News, 5/20/02 by Diane West

	Analysis Demonstrates Time to Response With FASLODEX® Injection Comparable to Anastrozole for Postmenopausal Women With Metastatic Breast Cancer Results from Phase III trials announced at 28th Annual San Antonio Breast Cancer Symposium SAN ANTONIO, Texas, Dec. 10 /PRNewswire-FirstCall/ -- An analysis of two Phase III studies evaluating t From PR Newswire, 12/10/05

	Hormone trial seeks volunteers - FYI Researchers are recruiting for a randomized, double-blinded phase III trial to assess the efficacy and tolerability of fulvestrant (Faslodex) injection. From OB/GYN News, 10/15/03

	New drugs 2003, part II IN THIS ARTICLE, you'll learn about eight more new drugs marketed in the first half of 2002. (For details on other new drugs first marketed in that period, ... From Nursing, 7/1/03 by Hussar, Daniel A

	Once-monthly treatment for refractory breast cancer The FDA has approved Faslodex (fulvestrant) injection for the treatment of hormone receptor-- positive metastatic breast cancer in postmenopausal women ... From Nursing, 8/1/02

	New treatment for advanced breast cancer - Updates In April 2002, the FDA approved Faslodex (fulvestrant) for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women ... From FDA Consumer, 7/1/02

	Fulvestrant Promising for Advanced Breast Ca SAN ANTONIO -- Fulvestrant, the first in a new class of drugs known as estrogen receptor downregulators, shows great promise for the treatment of breast ... From OB/GYN News, 6/1/01 by Bruce Jancin

	AstraZeneca Provides Additional Support to Hurricane Victims Company launches relief efforts in partnership with Rotary Club of Houston to pledge additional support at AHA annual meeting WILMINGTON, Del., Nov. From PR Newswire, 11/17/05

Home

Contact

Resources

ebay